<DOC>
	<DOCNO>NCT00661167</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety tri-weekly ABI-007 recurrence unresectable gastric cancer patient receive one prior regimen contain fluoropyrimidine develop disease progression recurrence .</brief_summary>
	<brief_title>Phase II Study ABI-007 Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologically cytologically confirm gastric adenocarcinoma Received one prior regimen contain fluoropyrimidine analog develop disease progression recurrence Age : 20 74 At least one measurable lesion RECIST criterion History Taxans use Patients another active malignancy Preexisting peripheral neuropathy Grade 2 , 3 , 4 ( per CTCAE ) Chronic treatment steroid</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>